Peptides DB
Research-centric peptide and protocol reference hub
Study 88 of 88HGH (Somatropin) literatureGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · Observational2026

Dose optimization and safety of long-acting pegylated growth hormone in pubertal idiopathic short stature: A retrospective real-world group study.

Higher doses of PEG-rhGH appear to enhance growth outcomes in children with idiopathic short stature, but the clinical relevance of these findings should be considered carefully.

Read at Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research SocietyAdd to compare

Where it sits

this study against the rest of the hgh (somatropin) corpus
4
Preclinical
59
Observational · this one
1
Open-label
15
Randomised
9
Reviews

Summary and findings

This study analyzed the efficacy and safety of polyethylene glycol recombinant long-acting human growth hormone (PEG-rhGH) in 118 children with idiopathic short stature (ISS). It found that higher doses of PEG-rhGH resulted in greater height standard deviation score (HtSDS) gains and higher height velocity (HV). No serious adverse events were reported.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001 for high-dose vs. low-dose groups.n=1182026

Abstract

The authors’ words, as Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society supplied them

<h4>Purpose</h4>Given the lack of established dosing strategies for polyethylene glycol recombinant long-acting human growth hormone (PEG-rhGH) in pubertal patients with idiopathic short stature (ISS), it is necessary to develop optimal dosing regimens. This study aims to explore relevant clinical and prognostic factors influencing the efficacy of PEG-rhGH in pubertal ISS patients, and to evaluate the efficacy and safety of higher-dose PEG-rhGH.<h4>Methods</h4>A retrospective real-world group study analyzed efficacy and safety data from 118 children with ISS treated with PEG-rhGH.<h4>Results</h4>Following 12 months of PEG-rhGH treatment in children with ISS:① Pre-pubertal demonstrated significantly greater gain in height standard deviation score (HtSDS) and higher height velocity(HV) than the pubertal group (ΔHtSDS: 0.98 ± 0.47 vs. 0.52 ± 0.33, p < 0.001; HV: 10.65 ± 1.55 cm/year vs. 9.98 ± 1.76 cm/year, p = 0.035).②The high-dose group showed significantly greater gain in HtSDS and higher HV compared to the low-dose group (ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001; HV: 11.99 ± 1.25 cm/year vs. 9.69 ± 1.43 cm/year,p < 0.001).③HtSDS gain exhibited a dose-dependent effect with PEG-rhGH treatment. ④The high-dose group did not exhibit additional treatment-emergent adverse events (TRAEs) compared to the low-dose group.<h4>Conclusion</h4>Pubertal constitutes a negative predictive factor for PEG-rhGH efficacy in children with ISS, and the efficacy of PEG-rhGH is dose-dependent. Therefore, higher dose (≥0.23 mg/kg/week) of PEG-rhGH treatment is beneficial to enhance the efficacy of pubertal ISS patients. No serious adverse events were observed.<h4>What is known</h4>WHAT IS NEW.

Background

This paper addresses the dosing strategies for polyethylene glycol recombinant long-acting human growth hormone (PEG-rhGH) in pubertal patients with idiopathic short stature (ISS). Prior knowledge indicated that dosing regimens for PEG-rhGH were not well established, necessitating further exploration of its efficacy and safety. Understanding the impact of dosing on treatment outcomes is critical for optimizing care in this population.

Methods

A retrospective real-world group study was conducted involving 118 children with ISS treated with PEG-rhGH. The study analyzed data over a 12-month treatment period. Primary outcomes included height standard deviation score (HtSDS) and height velocity (HV), with comparisons made between pre-pubertal and pubertal groups as well as high-dose and low-dose groups.

Results

Following 12 months of PEG-rhGH treatment, the primary endpoint showed a significant difference in HtSDS gain between pre-pubertal and pubertal groups, with ΔHtSDS of 0.98 ± 0.47 vs. 0.52 ± 0.33, p < 0.001. Additionally, the high-dose group demonstrated a greater HtSDS gain compared to the low-dose group, with ΔHtSDS of 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001.

Interpretation

The findings suggest that higher doses of PEG-rhGH are associated with improved height outcomes in children with ISS, consistent with the notion of dose-dependency. However, the clinical significance of the observed differences should be interpreted cautiously, particularly given the retrospective nature of the study and the absence of a control group. These factors may limit the ability to draw definitive conclusions about the efficacy and safety of PEG-rhGH in this population.

Key findings

  • ΔHtSDS: 0.98 ± 0.47 vs. 0.52 ± 0.33, p < 0.001 for pre-pubertal vs. pubertal groups.
  • HV: 10.65 ± 1.55 cm/year vs. 9.98 ± 1.76 cm/year, p = 0.035 for pre-pubertal vs. pubertal groups.
  • ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001 for high-dose vs. low-dose groups.
  • HV: 11.99 ± 1.25 cm/year vs. 9.69 ± 1.43 cm/year, p < 0.001 for high-dose vs. low-dose groups.
  • No serious adverse events were observed.

Limitations

  • Retrospective study design.
  • No control group for comparison.
  • Single-site study may limit generalizability.
  • Short follow-up period of 12 months.

Elsewhere in the HGH (Somatropin) corpus

AOnce-weekly somatrogon versus daily somatropin in pediatric growth hormone deficiency: A systematic review and meta-analysis.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · Not reported in abstract.reviewDAn assessment of the global usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · 24 (65%) had a reported completion time less than 15 min.reviewCDeciphering the In Vivo Fate of PEGylated rhGH via a Molecular Ruler-Based MS Strategy.Analytical chemistry · plasma half-life t1/2 = 26.83 hAnimalBLong-acting growth hormone therapy in Chinese children with idiopathic short stature: efficacy evaluation and influencing factors.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · n=180 · -1.47 ± 0.31 HtSDS vs -1.63 ± 0.48 in control, p<0.001 after 12 monthsHumanDGH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · Complete GHD showed greater first-year height velocity (HV) than ISS (MD +0.80 cm/year; 95% CI 0.52-1.08).reviewBInfluence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study.Journal of endocrinological investigation · 2026 · IGF-I SDS increased significantly in both groups (p<0.001).Human